There are more viable covid treatments undergoing, and some of them have shown massive efficiency. One of them seems to come from Pfizer, the company that’s been in the spotlight a lot due to their covid vaccines.
Pfizer final covid pill analysis
CNBC notes that Pfizer said the final analysis of its antiviral Covid-19 pill still showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients.
More than that, it’s been revealed that recent lab data suggests the fact that the drug retains its effectiveness against the fast-spreading Omicron variant of the coronavirus.
It’s also important to note that last month Pfizer said the oral medicine was “around 89% effective in preventing hospitalizations or deaths when compared to placebo based on interim results in around 1,200 people.”
The data disclosed on Tuesday includes more than 1,000 people.
CNBC also notes something pretty disturbing:
“Nobody in the trial who got the Pfizer treatment died, compared with 12 deaths among placebo recipients.”
The same publication also notes the following:
“The Pfizer pills are taken with the older antiviral ritonavir every 12 hours for five days beginning shortly after onset of symptoms. If authorized, the treatment will be sold as Paxlovid.”
CNBC also noted that Pfizer also released early data from a second clinical trial showing that the treatment reduced hospitalizations by around 70% in around 600 standard-risk adults.
“It’s a stunning outcome,” Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.
He continued and said the following:
“We’re talking about a staggering number of lives saved and hospitalizations prevented. And of course, if you deploy this quickly after infection, we are likely to reduce transmission dramatically.”
Speaking about efficiency, earlier today, we revealed that a new study is addressing important conclusions about the novel variant of the virus.